Cell-dependent interference of a series of new 6-aminoquinolone derivatives with viral (HIV/CMV) transactivation

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 5, 2005, Pages 847-855

  Stevens, Miguel ^a   Balzarini, Jan ^a   Tabarrini, Oriana ^b   Andrei, Graciela ^a   Snoeck, Robert ^a   Cecchetti, Violetta ^b   Fravolini, Arnaldo ^b   De Clercq, Erik ^a   Pannecouque, Christophe ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Latency; TAR; Tat

Indexed keywords

AMINOQUINOLINE DERIVATIVE; ANTIRETROVIRUS AGENT; GREEN FLUORESCENT PROTEIN; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS RNA; WC 12; WC 13; WM 12; WM 14; WM 16; WM 21;

ANTIVIRAL ACTIVITY; ARTICLE; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROMOTER REGION; STRUCTURE ANALYSIS; TRANSACTIVATION; VIRUS EXPRESSION; VIRUS INHIBITION; VIRUS REPLICATION;

AMINOQUINOLINES; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CYTOMEGALOVIRUS; GENES, IMMEDIATE-EARLY; GREEN FLUORESCENT PROTEINS; HIV; HIV LONG TERMINAL REPEAT; HUMANS; MICE; PEPTIDE ELONGATION FACTOR 1; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; RNA, VIRAL; TETRADECANOYLPHORBOL ACETATE; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS REPLICATION;

EID: 27744576773     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki328     Document Type: Article

References (31)

1. Chun TW, Carruth L, Finzi D et al. Quantification of latent reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387: 183-8.
2. Chun TW, Stuyver L, Mizell SB et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997; 94: 13193-7.
3. + T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci USA 2003; 100: 1908-13.
4. Wong JK, Hezareh M, Günthard HF et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278: 1291-5.
5. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5: 512-17.
6. + T cells. Nat Med 2003; 9: 727-8.
7. + T cells in vivo. J Virol 2004; 78: 9105-14.
8. Lin X, Irwin D, Kanazawa S et al. Transcriptional profiles of latent human immunodeficiency virus in infected individuals: Effects of Tat on the host and reservoir. J Virol 2003; 77: 8227-36.
9. Andriole VT, ed. The Quinolones. London: Academic Press, 1988.
10. Baba M, Okamoto M, Makino M et al. Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyl-oxoquinoline derivatives. Antimicrob Agents Chemother 1997; 41: 1250-5.
11. Baba M, Okamoto M, Kawamura M et al. Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives. Mol Pharmacol 1998; 53: 1097-1103.
12. Kashiwase H, Momota K, Ohmine T et al. A new fluoroquinolone derivative exhibits inhibitory activity against human immunodeficiency virus type 1 replication. Chemotherapy 1999; 45: 48-55.
13. Okamoto H, Cujec TP, Okamoto M et al. Inhibition of the RNA-dependent transactivation and replication of human immunodeficiency virus type 1 by a fluoroquinoline derivative K-37. Virology 2000; 272: 402-8.
14. Parolin C, Gatto B, Del Vecchio C et al. New anti-human immunodeficiency virus type 1 6-aminoquinolones: Mechanism of action. Antimicrob Agents Chemother 2003; 47: 889-96.
15. Cecchetti V, Parolin C, Moro S et al. 6-Aminoquinolones as new potential anti-HIV agents. J Med Chem 2000; 43: 3799-3802.
16. Richter S, Parolin C, Gatto B et al. Inhibition of human immunodeficiency virus type 1 Tat-trans-activation-responsive region interaction by an antiviral quinolone derivative. Antimicrob Agents Chemother 2004; 48: 1895-9.
17. Tabarrini O, Stevens M, Cecchetti V et al. Structure modifications of 6-aminoquinolones with potent anti-HIV activity. J Med Chem 2004; 47: 5567-78.
18. Daelemans D, De Clercq E, Vandamme AM. A quantitative GFP-based bioassay for the detection of HIV-1 Tat transactivation inhibitors. J Virol Methods 2001; 96: 183-8.
19. + cell model of chronic infection. J Virol 1991; 65: 4645-53.
20. Caputo A, Sodroski JG, Haseltine WA. Constitutive expression of HIV-1 Tat protein in human Jurkat T cells using a BK virus vector. J Acquir Immune Defic Syndr 1990; 3: 372-9.
21. Folks TM, Justement J, Kinter A et al. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 1987; 238: 800-2.
22. Pauwels R, Balzarini J, Baba M et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988; 20: 309-21.
23. Poli G, Kinter A, Justement JS et al. Tumor necrosis factor α functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci USA 1990; 87: 782-5.
24. -ΔΔCT method. Methods 2001; 25: 402-8.
25. Stevens M, Pannecouque C, De Clercq E et al. Novel human immunodeficiency virus (HIV) inhibitors that have a dual mode of anti-HIV action. Antimicrob Agents Chemother 2003; 47: 3109-16.
26. + T lymphocytes in vivo. J Virol 2003; 77: 7383-92.
27. Kao SY, Calman AF, Luciw PA et al. Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature 1987; 330: 489-93.
28. Uetsuki T, Naito A, Nagata S et al. Isolation and characterization of the human chromosomal gene for polypeptide chain elongation factor-1α. J Biol Chem 1989; 264: 5791-8.
29. Karn J. Tackling Tat. J Mol Biol 1999; 293: 235-54.
30. Kim YK, Bourgeois CF, Isel C et al. Phosphorylation of the RNA polymerase II carboxyl-terminal domain by CDK9 is directly responsible for human immunodeficiency virus type 1 Tat-activated transcriptional elongation. Mol Cell Biol 2002; 22: 4622-37.
31. Wei P, Garber ME, Fang SM et al. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 1998; 92: 451-62.